← All trials
NCT05029999
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- Oct 31, 2024
- Completion date
- Oct 31, 2024
- First posted
- Sep 1, 2021
- Last posted
- Nov 30, 2021
- Enrollment
- 45
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- The University of Texas, DallasLead sponsor
- The University of Texas, DallasOverall official - principal investigator
- The University of Texas, DallasReponsible party - principal investigator
- Celldex TherapeuticsCollaborator
- Gateway for Cancer ResearchCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.